Corpus Intelligence RCM Diligence — Seeking Alpha Market Intel 2026-04-25 23:31 UTC
RCM Diligence — Seeking Alpha Market Intel
Public comps × PE deal flow × curated news
🛡️ Public data only — no PHI permitted on this instance.
Seeking Alpha · Market Intelligence
Healthcare public-market + PE snapshot
14 public comps · 12 PE transactions · 23 curated headlines · refreshed quarterly from public filings + aggregated analyst consensus
Most recent covered transaction: Harvest Partners → Advanced Dermatology & Cosmetic Surgery on 2026-04-12 at 12.8x (+0.0× vs sector median 12.8×).
Market read: Healthcare PE deal flow is currently most active in Audax Group, Harvest Partners, Welsh Carson Anderson & Stowe. Public hospital comp multiples are stabilizing at 9.0× EV/EBITDA — partners underwriting rural/mid-sized acquisitions should target entry multiples at a discount to that public band given the small-target size penalty.
Hospital peer median
9.00×
inside 7.50×–10.00× 5-yr norm
HCA
BUY
HCA Healthcare
8.9×
EV / EBITDA TTM
EV: $120.1B · Rev: $71.2B
Op margin: 16.9% · Debt/EBITDA: 3.1×
Analyst PT: $345 (22 ratings)
THC
BUY
Tenet Healthcare
8.8×
EV / EBITDA TTM
EV: $32.3B · Rev: $20.8B
Op margin: 14.2% · Debt/EBITDA: 4.0×
Analyst PT: $182 (18 ratings)
CYH
HOLD
Community Health Systems
9.5×
EV / EBITDA TTM
EV: $12.8B · Rev: $12.5B
Op margin: 8.9% · Debt/EBITDA: 8.6×
Analyst PT: $5 (11 ratings)
UHS
BUY
Universal Health Services
7.4×
EV / EBITDA TTM
EV: $17.4B · Rev: $15.6B
Op margin: 11.5% · Debt/EBITDA: 1.4×
Analyst PT: $235 (14 ratings)
EHC
BUY
Encompass Health
11.0×
EV / EBITDA TTM
EV: $12.6B · Rev: $5.3B
Op margin: 17.5% · Debt/EBITDA: 2.1×
Analyst PT: $109 (13 ratings)
ARDT
HOLD
Ardent Health Partners
10.2×
EV / EBITDA TTM
EV: $4.3B · Rev: $5.4B
Op margin: 7.8% · Debt/EBITDA: 3.6×
Analyst PT: $18 (8 ratings)
PRVA
BUY
Privia Health
21.7×
EV / EBITDA TTM
EV: $2.6B · Rev: $1.7B
Op margin: 4.9% · Debt/EBITDA: 0.8×
Analyst PT: $26 (10 ratings)
DVA
HOLD
DaVita Inc.
9.4×
EV / EBITDA TTM
EV: $22.7B · Rev: $12.8B
Op margin: 16.2% · Debt/EBITDA: 3.7×
Analyst PT: $165 (12 ratings)
FMS
HOLD
Fresenius Medical Care
7.8×
EV / EBITDA TTM
EV: $23.4B · Rev: $20.1B
Op margin: 9.4% · Debt/EBITDA: 3.5×
Analyst PT: $44 (9 ratings)
SGRY
BUY
Surgery Partners
12.9×
EV / EBITDA TTM
EV: $5.4B · Rev: $2.9B
Op margin: 8.2% · Debt/EBITDA: 5.5×
Analyst PT: $32 (11 ratings)
UNH
BUY
UnitedHealth Group
13.2×
EV / EBITDA TTM
EV: $562.0B · Rev: $395.0B
Op margin: 8.4% · Debt/EBITDA: 1.1×
Analyst PT: $630 (27 ratings)
ELV
BUY
Elevance Health
10.8×
EV / EBITDA TTM
EV: $138.0B · Rev: $180.5B
Op margin: 6.5% · Debt/EBITDA: 1.7×
Analyst PT: $555 (18 ratings)
MPW
HOLD
Medical Properties Trust
24.4×
EV / EBITDA TTM
EV: $13.4B · Rev: $0.9B
Op margin: 48.0% · Debt/EBITDA: 18.7×
Analyst PT: $6 (12 ratings)
WELL
BUY
Welltower
52.1×
EV / EBITDA TTM
EV: $112.0B · Rev: $8.2B
Op margin: 20.5% · Debt/EBITDA: 10.9×
Analyst PT: $155 (19 ratings)
Source: 10-K/10-Q filings, FactSet / CapIQ / Seeking Alpha aggregated analyst consensus. Values refresh quarterly; click any ticker to see the underlying comp in the public-comp library. Multiple color-coding: ≥12× premium · 8-12× in-line · <8× discount.
ACUTE HOSPITAL
NEGATIVE
AMBULATORY SURGERY
POSITIVE
PE median 14.2× (n=1)
ANESTHESIOLOGY
NEUTRAL
PE median 9.4× (n=1)
BEHAVIORAL
MIXED
BEHAVIORAL HEALTH
NEUTRAL
PE median 11.4× (n=2)
DENTAL DSO
MIXED
DERMATOLOGY
MIXED
PE median 12.8× (n=1)
DIALYSIS
MIXED
PE median 8.7× (n=1)
EMERGENCY MEDICINE
NEUTRAL
GASTROENTEROLOGY
NEUTRAL
PE median 10.5× (n=1)
HOME HEALTH
MIXED
PE median 9.0× (n=1)
HOSPICE
MIXED
MA RISK PRIMARY CARE
NEGATIVE
OPHTHALMOLOGY
MIXED
PE median 11.8× (n=1)
ORTHOPEDICS
NEUTRAL
PE median 13.1× (n=1)
RURAL ACUTE HOSPITAL
NEUTRAL
PE median 6.2× (n=1)
URGENT CARE
NEUTRAL
PE median 11.2× (n=1)
Tone = dominant sentiment across curated headlines; median multiple is the observed PE transaction EV/EBITDA for the sector in the last 6 months. The pairing surfaces the gap partners need to see — a sector with positive sentiment but compressed multiples often signals a buying opportunity.
2026-04-12
Advanced Dermatology & Cosmetic Surgery
Harvest Partners · DERMATOLOGY
12.8×
EV/EBITDA
$620M
deal size
Largest dermatology MSO deal of Q2 2026. Multiple compressed ~150bps from 2024 peak; HSR expanded reporting has lengthened tuck-in cadence in the sector.
2026-04-08
Ridgeline Surgical Partners
Welsh Carson Anderson & Stowe · AMBULATORY SURGERY
14.2×
EV/EBITDA
$1,100M
deal size
Premium multiple reflecting ASC migration thesis and favorable commercial payer mix. WCAS continues to lead the ASC-rollup space; this is their 3rd ASC platform.
2026-03-22
Meridian Anesthesia Group
New Mountain Capital · ANESTHESIOLOGY
9.4×
EV/EBITDA
$840M
deal size
Anesthesia multiples remain depressed vs 2022-2023 peaks; NSA IDR QPA recalculation proposed-rule publication creating overhang on the hospital-based physician sector.
2026-03-10
Prestige Behavioral Health
Audax Group · BEHAVIORAL HEALTH
10.8×
EV/EBITDA
$480M
deal size
Behavioral-health multiples holding firm on back of strong Medicaid reimbursement environment and continued demand tailwind. Medicaid state-exposure concentration remains the top diligence risk.
2026-02-28
Riverview Community Hospitals (3-facility carve-out)
Rural Healthcare Partners (Arsenal Capital vehicle) · RURAL ACUTE HOSPITAL
6.2×
EV/EBITDA
$185M
deal size
Rural hospital carve-out at discount multiple; reflects Medicare-heavy payer mix and thin CBSA economics. Buyer is a rural-platform specialist underwriting on site- neutral-proof service-line portfolio.
2026-02-10
Glendale GI Partners
Silversmith Capital Partners · GASTROENTEROLOGY
10.5×
EV/EBITDA
$320M
deal size
Classic GI platform deal with embedded ASC optionality; multiple anchored around the public-comp median for physician-group MSOs. Tuck-in strategy assumes pre-HSR- expanded-reporting cadence; partners should haircut.
2026-01-24
OakBridge Urgent Care Network
Nautic Partners · URGENT CARE
11.2×
EV/EBITDA
$410M
deal size
2026-01-15
Northstar Dialysis Holdings
Linden Capital Partners · DIALYSIS
8.7×
EV/EBITDA
$540M
deal size
Dialysis multiples recovered 50bps post-ESRD PPS CY2027 proposed +1.8% rate; sector still trades at discount to pre-2022 peak given MA reimbursement overhang.
2025-12-18
Westridge Eye Care Partners
FFL Partners · OPHTHALMOLOGY
11.8×
EV/EBITDA
$380M
deal size
2025-12-05
Centennial Home Health
Gryphon Investors · HOME HEALTH
9.0×
EV/EBITDA
$240M
deal size
Home-health multiples compressed vs 2022 post-PDGM implementation; buyers focusing on commercial-mix and MA-plan-network platforms.
2025-11-20
Aspen Orthopedics Partners
Audax Group · ORTHOPEDICS
13.1×
EV/EBITDA
$720M
deal size
Premium orthopedics multiple on ASC-attached platform; TEAM bundled payment rule overhang priced in via conditional earn-out on LEJR bundle margin.
2025-11-02
Meadowbrook Behavioral (predecessor)
Carlyle Group · BEHAVIORAL HEALTH
11.4×
EV/EBITDA
$1,250M
deal size
Top-of-range multiple for behavioral; priced on Medicaid demand tailwind and network effects of multi-state platform. Regulatory exposure concentrated in IMD exclusion rule status.
How to read: Each row is one closed or announced deal with sponsor, specialty, deal size and the published EV/EBITDA multiple. Use this as a negotiation anchor — partners bid into a market that just priced this deal at X× six weeks ago. Hover narratives for sponsor thesis and risk callouts.
Audax Group2
Harvest Partners1
Welsh Carson Anderson & Stowe1
New Mountain Capital1
Rural Healthcare Partners (Arsenal Capital vehicle)1
Silversmith Capital Partners1
Nautic Partners1
Linden Capital Partners1
Sponsors actively deploying capital in healthcare. Useful for competitive-bid forecasting — if Welsh Carson or Audax is circling the same sector, expect the auction floor multiple to widen 50-100bps.
2026-04-22
POSITIVESeeking Alpha · AMBULATORY SURGERY
Tenet posted $3.22 EPS vs $2.98 consensus, driven by the USPI ambulatory surgery segment. Management raised FY26 EBITDA guidance 3-5%. Sell-side consensus price target lifted to $182 average.
THCearningsascthcsite_neutral
2026-04-18
NEGATIVEModern Healthcare · ACUTE HOSPITAL
CMS finalised the CY2026 OPPS rule locking drug-administration reimbursement in grandfathered off-campus HOPDs at 40% of the on-campus rate. Affected hospital operators face ~$200-400M annual revenue erosion industry-wide.
HCATHCCYHUHSsite_neutraloppsregulatory
2026-04-14
NEGATIVESTAT · MA RISK PRIMARY CARE
CVS settled with DOJ over add-only retrospective chart reviews that inflated MA risk scores. Case was anchor for FCA exposure modeling in MA-risk-bearing platforms.
CVSfcamacoding_intensitydoj
2026-04-11
NEGATIVEModern Healthcare · MA RISK PRIMARY CARE
CMS published the final V28 HCC mapping for CY2027. Aggregate risk-score reduction projected at 3.12% — aligns with CY2025 pilot data. Providers with >60% MA mix should model $8-15M revenue compression per $500M NPR.
HCAUHSDVAv28cmsregulatorycoding_intensity
2026-04-08
NEGATIVEFierce Healthcare · ACUTE HOSPITAL
CMS TEAM bundled-payment mandatory enrollment effective Jan 1, 2026 covering 741 hospitals in 188 CBSAs. Two-thirds of participants projected to lose ~$1,350/case at baseline.
HCATHCUHSARDTCYHteambundled_paymentregulatory
2026-04-05
POSITIVEReuters · HOME HEALTH
UnitedHealth's $8.3B LHC acquisition cleared HSR review with no second request. Closing expected Q2 2026. Signal: home- health remains HSR-clean for vertical integration; contrast with USPI and NovaHealth precedents.
UNHm_and_ahsruhghome_health
2026-03-29
POSITIVEMertz Taggart · DENTAL DSO
Dental DSO private-transaction multiples held 11-13x EV/EBITDA in Q1 despite broader PE slowdown — driven by private-pay payer mix and absence of federal reimbursement overhang. Seven deals >$200M EV cleared in trailing 90 days.
rollupdsodentaltransaction_multiples
2026-03-27
NEUTRALReuters · EMERGENCY MEDICINE
Envision emerged from restructuring as a physician-owned vehicle rather than re-PE-sponsored. Market signal: NSA environment structurally incompatible with aggressive LBO structures on hospital-based physician groups.
nsabankruptcy_emergenceemergency_medicine
2026-03-22
POSITIVESeeking Alpha · DIALYSIS
Three sell-side shops upgraded DaVita following CMS CY2027 ESRD PPS preliminary rate release — 1.8% rate increase with no Medicare Advantage carveouts. Consensus price target moved from $145 to $165.
DVAanalyst_upgradedialysiscmsesrd
2026-03-15
NEGATIVESeeking Alpha · ACUTE HOSPITAL
HCA missed Q1 consensus EBITDA by 2.1% on site-neutral + TEAM headwinds; multiple compressed from 10.2x trailing 12mo to 8.9x. Analyst consensus cut FY26 EBITDA 4-6%.
HCAearningsmultiple_compression
2026-03-10
NEGATIVEPESP · ACUTE HOSPITAL
Connecticut HB 5316 passes Senate. REIT operational control banned effective Oct 1 2026; sale-leaseback bans effective Oct 1 2027. Adds to MA H.5159 enacted 2025 Q1.
MPWsale_leasebackregulatoryreitconnecticut
2026-03-06
MIXEDFierce Healthcare · EMERGENCY MEDICINE
Three mid-cap emergency medicine groups secured BCBS-TX par status 14 months after the broad OON termination cycle. ED groups' collections recovery averaging 58% of pre-termination run-rate — suggesting NSA pressure is bounded, not terminal.
nsabcbspar_restorationemergency_medicine
Public-comp category bands — median EV/EBITDA by sub-sector, sortable · CSV export wired
CategoryMedian EV/EBITDAP25P75# CompsLatest Review
AMBULATORY SURGERY13.00×11.50×14.50×
DIALYSIS8.60×7.90×9.30×
HEALTHCARE REIT38.00×24.00×52.00×
MANAGED CARE PAYER12.00×10.80×13.20×
MULTI SITE ACUTE AND BEHAVIORAL7.40×7.00×8.20×
MULTI SITE ACUTE HOSPITAL9.00×8.50×10.20×
PHYSICIAN GROUP ROLL UP20.00×17.50×24.00×
POST ACUTE REHAB11.00×10.50×12.00×
RURAL ACUTE HOSPITAL9.50×8.20×10.50×
Press ? for shortcuts · b to bookmark · ⌘K to jump